microtubule associated protein 7Genealiases: E-MAP-115 · EMAP115
Q-omics provides the consensus-scored MAP7 profile across patient tissues and cancer cell-line models. MAP7 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAP7 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, MAP7 protein abundance shows 28,831 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where MAP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP7 survival associations across molecular data types. MAP7 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP7 RNA expression–survival associations across cancer types. High MAP7 expression shows unfavorable associations in CESC, ESCA and LUAD, but favorable associations in KIRC, READ and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAP7 RNA expression.
This table summarizes MAP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP7 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LUSC, BLCA and HNSC. The KICH box plot shows higher MAP7 RNA expression in normal versus tumor tissue (log2 FC = −1.821, t-test p < 0.001).
This table shows molecular features associated with MAP7 in patient tissues and cancer cell lines. In patient samples, MAP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
